Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18242067 | 0.81 | GABRA1 (0.42) | — | |
| SCHEMBL16935678 | 0.79 | PNMT (0.44) | PNMTDPP4TAAR1LOXL2NCF1 | |
| SCHEMBL7517929 | 0.77 | APOBEC3G (0.41) | CYP2A6 | |
| SCHEMBL18241843 | 0.77 | MITF (0.37) | TAAR1KDM4E | |
| SCHEMBL27569881 | 0.76 | PNMT (0.46) | PNMTDPP4TAAR1LOXL2KDM4E | |
| SCHEMBL7959776 | 0.76 | PNMT (0.41) | PNMTDPP4TAAR1LOXL2NCF1 | |
| SCHEMBL7959778 | 0.76 | PNMT (0.41) | PNMTDPP4TAAR1LOXL2NCF1 | |
| SCHEMBL263092 | 0.74 | PNMT (0.44) | PNMTDPP4TAAR1LOXL2KDM4E | |
| SCHEMBL3595870 | 0.74 | PNMT (0.44) | PNMTDPP4TAAR1LOXL2KDM4E | |
| SCHEMBL3146119 | 0.74 | LMNA (0.55) | PNMTDPP4LOXL2KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | ARIVA MED GMBH (AT) | 2023-06-08 | — | — | US | claimed |
| EP-4135683-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | Nabriva Therapeutics GMBH (AT) | 2023-02-22 | — | — | EP | claimed |
| CN-115413238-A | Therapeutic use of pleuromutilin compounds | 纳布里瓦治疗有限责任公司 | 2022-11-29 | — | — | CN | claimed |
| WO-2021209596-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-10-21 | — | — | WO | claimed |
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | claimed |
| CN-105916499-B | 12-epi-pleuromutilins | 纳布里瓦治疗股份公司 | 2020-02-18 | — | — | CN | claimed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | claimed |
| EP-3096751-A1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics AG (AT) | 2016-11-30 | — | — | EP | claimed |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2016-11-17 | — | — | US | claimed |
| WO-2015110481-A1 | 12-EPI-PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2015-07-30 | — | — | WO | claimed |
| EP-1179529-A1 | NOVEL HYDROXAMIC ACID DERIVATIVES | Daiichi Fine Chemical Co., Ltd. (JP) | 2002-02-13 | — | — | EP | claimed |
| EP-1038864-A1 | NOVEL METALLOPROTEINASE INHIBITORS | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2000-09-27 | — | — | EP | claimed |
| US-20240208989-A1 | NOVEL 12-EPI-MUTILIN COMPOUNDS AND USES THEREOF | ARIVA MED GMBH (AT) | 2024-06-27 | — | — | US | disclosed |
| EP-4323366-A1 | NOVEL 12-EPI-MUTILIN COMPOUNDS AND USES THEREOF | Nabriva Therapeutics GMBH (AT) | 2024-02-21 | — | — | EP | disclosed |
| CN-117500809-A | Novel 12-epimeric-mollin compounds and uses thereof | 纳布里瓦治疗有限责任公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | disclosed |
| CN-1914205-A | Pyrazolo [3, 4-b ] pyridine compounds and their use as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2007-02-14 | — | — | CN | disclosed |
| EP-1179529-A1 | NOVEL HYDROXAMIC ACID DERIVATIVES | Daiichi Fine Chemical Co., Ltd. (JP) | 2002-02-13 | — | — | EP | disclosed |
| EP-1101492-A1 | NOVEL REMEDIES FOR ALLERGIC DISEASES | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2001-05-23 | — | — | EP | disclosed |
| EP-1038864-A1 | NOVEL METALLOPROTEINASE INHIBITORS | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2000-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208989-A1 | NOVEL 12-EPI-MUTILIN COMPOUNDS AND USES THEREOF | MTNR1A, MSH6, MSH2 | PNMT 2558/4885DPP4 1065/4885TAAR1 2460/4885 |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | MLN, TCF12, PLEC | PNMT 1745/4885DPP4 2444/4885TAAR1 1333/4885 |
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | MLN, PLEC, PELP1 | PNMT 1141/4885DPP4 339/4885TAAR1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.